ATE480559T1 - Verwendungen eines neurotrophischen faktors - Google Patents
Verwendungen eines neurotrophischen faktorsInfo
- Publication number
- ATE480559T1 ATE480559T1 AT05817611T AT05817611T ATE480559T1 AT E480559 T1 ATE480559 T1 AT E480559T1 AT 05817611 T AT05817611 T AT 05817611T AT 05817611 T AT05817611 T AT 05817611T AT E480559 T1 ATE480559 T1 AT E480559T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- patient
- neurotrophic factor
- condition
- parkinson
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title 1
- 102000007072 Nerve Growth Factors Human genes 0.000 title 1
- 239000003900 neurotrophic factor Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FI2005/050461 WO2007068784A1 (en) | 2005-12-14 | 2005-12-14 | Novel neurotrophic factor protein and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE480559T1 true ATE480559T1 (de) | 2010-09-15 |
Family
ID=38162600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05817611T ATE480559T1 (de) | 2005-12-14 | 2005-12-14 | Verwendungen eines neurotrophischen faktors |
Country Status (11)
Country | Link |
---|---|
US (4) | US20100285045A1 (de) |
EP (2) | EP1969003B8 (de) |
JP (1) | JP5236488B2 (de) |
AT (1) | ATE480559T1 (de) |
AU (1) | AU2005339101B2 (de) |
CA (1) | CA2633468C (de) |
DE (1) | DE602005023550D1 (de) |
DK (1) | DK1969003T3 (de) |
ES (1) | ES2352205T3 (de) |
PL (1) | PL1969003T3 (de) |
WO (2) | WO2007068784A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
JP6258197B2 (ja) * | 2011-06-09 | 2018-01-17 | ユニバーシティ オブ マイアミ | 網膜疾患の治療方法 |
FI20115870A0 (fi) * | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
JP6495270B2 (ja) | 2013-10-30 | 2019-04-03 | ザ ユニバーシティ オブ ウェスタン オーストラリア | 神経保護ペプチドを含有する医薬組成物 |
US20170252403A1 (en) * | 2014-10-06 | 2017-09-07 | Amarantus Bioscience Holdings, Inc. | Methods and compositions for treating retinal disorders |
JP7201432B2 (ja) | 2015-11-18 | 2023-01-10 | ヘランティス ファーマ ピーエルシー | 中枢神経系疾患の鼻腔内治療に使用するためのcdnfまたはmanfを含む組成物 |
SG11201910183SA (en) | 2017-05-04 | 2019-11-28 | Helsingin Yliopisto | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof |
WO2018220151A1 (en) * | 2017-06-02 | 2018-12-06 | Verhaert Peter Dominiek Emiel Maria | Mass spectrometry histochemistry of peptides from formaldehyde-fixed, paraffin-embedded tissue |
KR20200138798A (ko) | 2018-03-29 | 2020-12-10 | 헬싱인 일리오피스토 | C-말단 cdnf 단편, 이를 포함하는 약학적 조성물 및 그 용도 |
CN108925783B (zh) * | 2018-07-23 | 2021-09-21 | 浙江大学 | 烟粉虱manf基因或其表达的蛋白作为靶点在制备防治烟粉虱的药物中的应用 |
EP3838345A1 (de) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Makrocyclische peptide |
EP3838912A1 (de) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptide |
WO2023202835A1 (en) * | 2022-04-21 | 2023-10-26 | Instituto de Medicina Molecular João Lobo Antunes | Mesencephalic astrocyte-derived neurotrophic factor (manf) for increasing muscle regeneration |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (de) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmazeutische Zusammensetzung mit Gehalt an Urokinase |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (de) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US6071889A (en) | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5661033A (en) | 1992-11-25 | 1997-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Gene transfer using herpes virus vectors as a tool for neuroprotection |
US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
DE4311651A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
CA2160583A1 (en) | 1993-04-16 | 1994-10-27 | Stanley A. Plotkin | Recombinant cytomegalovirus vaccine |
WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
FR2716682B1 (fr) | 1994-01-28 | 1996-04-26 | Centre Nat Rech Scient | Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations. |
US5686278A (en) | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
FR2732357B1 (fr) | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
US5773289A (en) | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
US5622856A (en) | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
US6027931A (en) | 1995-08-03 | 2000-02-22 | Avigen, Inc. | High-efficiency AA V helper functions |
US5830727A (en) | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
US5770414A (en) | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
EP1220681A2 (de) | 1999-09-16 | 2002-07-10 | Prescient Neuropharma Inc. | Überlebensfördernden neuronalen dopaminergischen faktoren und deren verwendungen |
CA2393616A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
WO2001055320A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU5091201A (en) | 2000-03-21 | 2001-10-03 | Curagen Corp | Vegf-modulated genes and methods employing them |
EP1368468A4 (de) * | 2001-02-23 | 2005-02-16 | Human Genome Sciences Inc | Menschliche sezernierte proteine |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
US20040053250A1 (en) * | 2001-03-05 | 2004-03-18 | Tang Y. Tom | Novel arginine-rich protein-like nucleic acids and polypeptides |
EP1373502B8 (de) * | 2001-03-20 | 2010-12-22 | Amarantus Therapeutics, Inc. | Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen |
CA2441327A1 (en) | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
US7452969B2 (en) * | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
US20060195915A1 (en) * | 2002-08-30 | 2006-08-31 | Licentia Ltd. | Novel neurotrophic factor protein and uses thereof |
-
2005
- 2005-12-14 WO PCT/FI2005/050461 patent/WO2007068784A1/en active Application Filing
- 2005-12-14 ES ES05817611T patent/ES2352205T3/es active Active
- 2005-12-14 JP JP2008545024A patent/JP5236488B2/ja not_active Expired - Fee Related
- 2005-12-14 DE DE200560023550 patent/DE602005023550D1/de active Active
- 2005-12-14 AT AT05817611T patent/ATE480559T1/de not_active IP Right Cessation
- 2005-12-14 PL PL05817611T patent/PL1969003T3/pl unknown
- 2005-12-14 CA CA 2633468 patent/CA2633468C/en active Active
- 2005-12-14 AU AU2005339101A patent/AU2005339101B2/en not_active Ceased
- 2005-12-14 EP EP20050817611 patent/EP1969003B8/de active Active
- 2005-12-14 DK DK05817611T patent/DK1969003T3/da active
-
2006
- 2006-12-14 WO PCT/FI2006/050557 patent/WO2007068803A1/en active Application Filing
- 2006-12-14 US US12/086,397 patent/US20100285045A1/en not_active Abandoned
- 2006-12-14 EP EP06830935.0A patent/EP1960426B1/de active Active
-
2008
- 2008-02-26 US US12/037,535 patent/US9127082B2/en active Active
-
2011
- 2011-04-15 US US13/088,233 patent/US8980821B2/en not_active Expired - Lifetime
-
2014
- 2014-10-17 US US14/517,508 patent/US20190153052A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100285045A1 (en) | 2010-11-11 |
EP1969003A1 (de) | 2008-09-17 |
US20190153052A1 (en) | 2019-05-23 |
JP2009519028A (ja) | 2009-05-14 |
AU2005339101B2 (en) | 2013-01-10 |
EP1960426A1 (de) | 2008-08-27 |
AU2005339101A1 (en) | 2007-06-21 |
PL1969003T3 (pl) | 2011-05-31 |
US20110251132A1 (en) | 2011-10-13 |
US20080269154A1 (en) | 2008-10-30 |
CA2633468A1 (en) | 2007-06-21 |
EP1960426B1 (de) | 2014-04-02 |
US8980821B2 (en) | 2015-03-17 |
DK1969003T3 (da) | 2010-12-13 |
JP5236488B2 (ja) | 2013-07-17 |
CA2633468C (en) | 2014-02-18 |
WO2007068784A1 (en) | 2007-06-21 |
EP1969003A4 (de) | 2009-03-25 |
EP1969003B1 (de) | 2010-09-08 |
DE602005023550D1 (de) | 2010-10-21 |
ES2352205T3 (es) | 2011-02-16 |
WO2007068803A1 (en) | 2007-06-21 |
EP1960426A4 (de) | 2009-07-08 |
US9127082B2 (en) | 2015-09-08 |
EP1969003B8 (de) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE480559T1 (de) | Verwendungen eines neurotrophischen faktors | |
NZ595063A (en) | Polypeptides from neisseria meningitidis | |
MX338338B (es) | Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias. | |
MX2008007697A (es) | Nanocumulos para la distribucion de farmacos. | |
EP2175834B8 (de) | Glp-1-fc fusionsprotein-formulierung | |
WO2007125501A3 (en) | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness | |
IL189546A0 (en) | Therapy for the treatment of disease | |
RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
ATE521343T1 (de) | Im mund zerfallende zusammensetzungen von rasagilin | |
NZ606480A (en) | Albumin binding peptide-mediated disease targeting | |
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
EP1261340A4 (de) | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit | |
US20220370360A1 (en) | Compositions for treating viral infections and methods for same | |
BR0211604A (pt) | Inibidores de integrina para o tratamento de doenças do olho | |
DE602006012115D1 (de) | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga | |
BR0316523A (pt) | Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente | |
CA2480429A1 (en) | Novel therapeutical use of agonist ligands specific to g2a receptor | |
WO2004043373A3 (en) | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
WO2007125142A8 (es) | Péptidos lineales antimicrobianos | |
WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
ATE554793T1 (de) | Konjugat | |
WO2007096596A3 (en) | Use of il-8 for the treatment of crohn' s disease | |
ATE410156T1 (de) | Zusammensetzungen aus deramciclan und opioiden zur verwendung als schmerzmittel | |
WO2008145095A3 (de) | Aminosäure-mineral-peptid-komplex, insbesondere quantenmechanisch modifiziert, als arzneimittel zur behandlung von demenzerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |